Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$0.01
+0.00 (+100.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-45489.00 · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$570695
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2698.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2022 · 1 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-93680.0 · FCF $-10268.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2022 | 2021 |
|---|---|---|---|
| Income Statement | |||
| Net Income | $-93680.00 | $-93680.00 | $-74082.00 |
| EBITDA | $-100092.00 | $-100092.00 | $-79542.00 |
| EPS | -0.04 | -0.04 | -0.03 |
| Balance Sheet | |||
| Current Ratio | 0.00 | 0.00 | — |
| Cash Flow | |||
| Free Cash Flow | $-10268.00 | $-10268.00 | $-80710.00 |
| Returns | |||
| ROE | -2698.2% | -2698.2% | -76.3% |
| Valuation | |||
| P/B | 7.49 | 7.49 | 2.64 |
| Growth & Yield | |||
| EPS Growth | -33.3% | -33.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+100.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.04
Residual
+100.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.